Clarity secures IND from FDA for radiotracer for prostate cancer

By staff writers

June 6, 2022 -- Clarity Pharmaceuticals has secured investigational new drug approval (IND) from the U.S. Food and Drug Administration (FDA) to start a phase II clinical trial of a radiotracer for detecting cancer in asymptomatic patients.

The clearance is for Clarity's SAR-Bombesin agent, which detects prostate cancer in men who are prostate specific membrane antigen (PSMA)-negative, according to the firm. The trial, called Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer trial (SABRE), will include up to 50 PSMA-negative men who have biochemical recurrence of the disease after surgery or radiation.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking